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Psoriasis is associated with HLA-Cw6, and
Caucasians who carry this allele have about a 10-fold
increased risk of developing psoriasis. We have HLA-
C typed 369 patients with familial psoriasis and com-
pared the clinical features of the patients carrying
HLA-Cw6 against those carrying other HLA-C
types. Some striking clinical differences were
observed between the two groups. Patients who are
Cw6 positive had a lower age at onset (p = 3 3 10±7).
Cw6-positive women had an earlier disease onset
than Cw6-positive men (p = 0.02), but such a differ-
ence was not observed for the Cw6-negative patients.
The guttate-type onset of psoriasis was mostly con-
®ned to this group (p= 2 3 10±4) and persistent
disseminated guttate-like papules were also pre-
dominantly observed in the Cw6-positive patients
(p < 10±4). The Cw6-positive patients also had
more extensive plaques on their arms, legs, and
trunk (p = 0.001), more severe disease (p = 0.003),
higher incidence of the Koebner's phenomenon
(p = 0.005), reported more often that their psoriasis
got worse during or after throat infections (p = 0.02),
and more often a favorable response to sunlight
(p = 0.008) In contrast, dystrophic nail changes
were more common in the Cw6-negative patients
(p = 0.002) and also psoriatic arthritis, although this
was not signi®cant (p = 0.135). It is concluded that
patients with psoriasis have different clinical features
depending on whether they are HLA-Cw6 positive
or negative. Key words: age of onset/clinical features/
HLA-Cw6/psoriasis. J Invest Dermatol 118:362±365, 2002
P
soriasis af¯icts approximately 2% of Caucasians, but is
found worldwide in all populations. Although often
overlapping, several clinical forms of psoriasis have been
de®ned. Chronic plaque psoriasis (psoriasis vulgaris) is
the type affecting approximately 90% of the patients and
is the most common form of presentation in adults (Fry, 1988).
Guttate psoriasis, characterized by a sudden and generalized
appearance of small red papules, occurs preferentially in children,
adolescents, and young adults, and up to 70% of these patients may
eventually develop the chronic plaque form of psoriasis (Williams et
al, 1976; Martin et al, 1996). A clear association has been established
between acute guttate psoriasis and infections by group A b-
hemolytic streptococci (Telfer et al, 1992), and streptococcal
infections may also cause exacerbation of chronic psoriasis
(Wardrop et al, 1998). In some patients lesions develop at the sites
of trauma, especially during active phases of the disease (Koebner's
phenomenon). Seborrhoeic psoriasis, which is mainly localized
around the sides of the nose, mouth, eyes, and in intertriginous
areas or the center of the chest, commonly coexists with chronic
plaque psoriasis. About 15% of psoriasis patients may also develop a
chronic arthritis (Espinoza et al, 1992). Increased proliferation and
turnover of keratinocytes is a characteristic feature that distinguishes
psoriasis from other in¯ammatory skin diseases (Fry, 1988). The
pathogenesis of the disease is not yet fully understood, but it is
believed to have an autoimmune basis and to be mediated by the
Th1 type of lymphocytes (Schlaak et al, 1994; Valdimarsson et al,
1995). Population and twin studies suggest strong heritable factors
(Lomholt, 1963; Brandrup et al, 1982; Duffy et al, 1993), and
linkage with several loci has been reported, including chromosomes
4q (Matthews et al, 1996), 6p (Trembath et al, 1997), 17q
(Tomfohrde et al, 1994), 19p (Lee et al, 2000) and 3q (Enlund et al,
1999) but only the major histocompatibility complex (MHC) on
chromosome 6 has been con®rmed by independent linkage studies
reporting LOD scores of genome wide signi®cance (LOD score
> 3.7) (Burden et al, 1998). The MHC region has for a long time
been thought to contain a risk allele for psoriasis on the basis of its
association to certain HLA-alleles (Russell et al, 1972), most notably
Cw6 (Tiilikainen et al, 1980; Mallon et al, 1999).
Two main types of psoriasis vulgaris have been proposed mainly
on the basis of bimodal distribution of the age at onset and
inheritance; type I with onset before or at the age of 40 y, positive
family history, and frequent association with Cw6; and type II with
onset after the age of 40 y, negative family history, and a normal
frequency of the Cw6 allele (Henseler and Christophers, 1985). It
has also been reported that Cw6-positive patients have an earlier
disease onset than Cw6-negative patients (Ikaheimo et al, 1996;
Enerback et al, 1997).
We have investigated 369 psoriasis patients belonging to 73
Icelandic families with a high incidence of psoriasis and observed
certain distinct clinical differences between Cw6-positive and
Cw6-negative patients.
MATERIALS AND METHODS
Study cohort and clinical evaluation We evaluated 369 psoriasis
patients belonging to 73 extended families with a high incidence of
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psoriasis ranging from three to 27 patients in different families. The
proband of each family was selected on the basis of at least one affected
®rst-degree relative. The clinical assessment was carried out and recorded
before patients were typed for HLA-C. The patients were all examined
by either of the same two physicians who were specially trained in
diagnostic evaluation and staging of psoriasis. A detailed clinical history
was obtained by a structured questionnaire, including age, site and mode
of onset, acute guttate psoriasis episodes, Koebner's phenomenon,
psoriatic arthritis, and changes during infections, stressful periods, and
other environmental factors. A careful physical examination was also
carried out and the distribution and the size of the plaques recorded.
Besides the characteristic chronic plaques, disseminated red papules, 1±
10 mm in diameter scattered between chronic plaques were also specially
recorded; this pattern of psoriasis has been referred to as the eruptive
type (Brenner et al, 1978). The patients had to have at least one
unequivocal psoriatic plaque at the time of the examination to be
included as affected in this analysis.
Four types of psoriasis associated nail changes were recorded, namely:
pitting, onycholysis, subungual hyperkeratosis, and dystrophy. Nail
changes were only recorded for the ®ngers, because of a high frequency
of fungal infections in toenails(Gudnadottir et al, 1999) that often can
mimic psoriatic nail changes. Patients with seborrhoeic or pustular
psoriasis or only a history of guttate psoriasis were not included if they
did not have any typical chronic psoriatic plaques at the time of
examination. Patients were recorded as having psoriatic arthritis only if
they had been diagnosed and treated for psoriatic arthritis by a
rheumatologist.
Scoring of disease severity Two types of disease severity scoring
systems were designed in consultation with an experienced
dermatologist. First, disease severity was scored from 1 to 4 for each
patient according to the criteria summarized in Table I. They were
mainly based on the extent and in¯ammatory activity of the plaques and
papules at the time of the examination but also on the treatment that the
patients had been given or were receiving at the time of the
examination. Patients with mild skin disease (< 5% of body surface),
therefore, got a severity score of 2 if they also had psoriatic arthritis.
Similarly, patients with arthritis and body surface involvement of 5±20%
scored 3. Initially, several patients were scored independently by the
clinicians who subsequently scored all the patients and the dermatologist
who helped to devise this scoring system; there was very good
agreement between the different observers. Secondly, disease severity was
also scored only in terms of the extent of the skin lesions at the time of
the examination. Lastly, the data were also analyzed by excluding
patients with psoriatic arthritis because they tended to be more
frequently on systemic treatments, especially methotrexate, which
suppresses skin lesions.
HLA typing All family members and 540 nonpsoriatic controls were
typed for all known HLA-C alleles using a Dynal HLA-C SSP Low-
resolution kit (Dynal Biotech Ltd, Merseyside, UK), which is a
polymerase chain reaction-based method, as instructed by the
manufacturer.
Statistical analysis Differences between the two groups in the age of
onset and disease severity were analyzed by the Mann±Whitney U test,
but the Fischer's exact test was used for comparing the frequencies of
variables between the groups.
RESULTS
Of the 369 patients, 247 (66,9%) were Cw6 positive and the
remaining 122 patients (33.1%) had other C alleles (Cw6
negatives).
Only 14 patients could not recall when their disease began. The
mean age at onset was 17.2 y (range 0.6±70 y) in the Cw6-positive
group compared with 24.5 y (range 1±72 y) in the Cw6-negative
group (p = 3 3 10±7) (Fig 1). Interestingly, women in the Cw6-
positive group had earlier disease onset than the males in this group
(16.3 vs 18.6 y, p = 0.02), but there was no difference in this
respect between women and males in the Cw6-negative group
(24.8 vs 24.0 y, respectively, data not shown). Only nine of 238
patients (4%) in the Cw6-positive group reported disease onset after
the age of 40 y compared with 18 of 117 (15%) in the Cw6-
negative group (p = 0.0002). The Cw6-positive patients also had an
earlier age at onset when only those who developed the disease
before the age of 40 y were analyzed (p = 0.004).
Acute guttate onset was mostly con®ned to the Cw6-positive
group (31 vs 2, p = 0.0002) but apart from that the groups did not
Table I. The criteria used for scoring disease severitya
Very severe (4) Severe (3) Moderate (2) Mild (1)
> 50% body area 20±50% body area 5±20% body area < 5% body area
or or or no treatment
continuous oral treatment intermittent oral treatment guttate disease or
or or or periodical local treatment
mutilating arthritis psoralen + ultraviolet A treatment ultraviolet B
or or
extensive disabling lesions
in hands or feet
extensive local treatment
or
or arthritis (mild)
severe arthritis
Figure 1. The age at onset of psoriasis in the Cw6-positive and
Cw6-negative patients. The Cw6-positive patients developed the
disease at an earlier age (p = 3 3 10±7).
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show a signi®cant difference with respect to the sites of onset
(Fig 2). Disseminated guttate-like papular lesions distributed
alongside typical psoriatic plaques (eruptive psoriasis) were
observed in 48 patients in the Cw6-positive group, but in only
®ve patients in the Cw6-negative group (p = 3 3 10±5, Fig 3). Of
these 48 Cw6-positive patients with eruptive psoriasis, 13 presented
initially with an acute guttate psoriasis, which was signi®cantly
higher than for the remaining Cw6-positive patients (p = 0.0002),
whereas none of the ®ve Cw6-negative eruptive patients presented
with an acute guttate episode. Taken together the guttate-type
psoriasis lesions were predominantly observed in the Cw6-positive
group (68 vs 5, p = 1 3 10±8). It should be noted in this context that
patients in the Cw6-positive group reported signi®cantly more
often that their psoriasis had got worse during infections, predom-
inantly of the throat (p = 0.02).
Patients who were Cw6-positive had more widely distributed
plaques than the Cw6-negative patients (Fig 3). Thus, at exam-
ination 169 (68%) of the Cw6-positive patients had plaques at more
than two different symmetric sites compared with 62 (51%) in the
Cw6-negative group (p = 0.001). The mean disease severity score
was also higher in the Cw6-positive group (1.67 vs 1.45,
p = 0.005), and a history of psoriatic lesions at the site of trauma
(Koebner's phenomenon) was also more commonly reported in the
Cw6-positive patients (67 vs 17, p = 0.005). There was no
signi®cant association within the Cw6-positive group between
early age of onset and the occurrence of the Koebner's phenom-
enon. As psoriatic arthritis had a relatively strong impact on the
severity score and arthritis was more common in the Cw6-negative
group, disease severity was also analyzed by excluding patients with
psoriatic arthritis and, as expected, the difference between the
groups increased (1.62 vs 1.27, p = 0.0003).
Patients who were Cw6-positive reported more often bene®cial
effects of sunlight (99 vs 31, p = 0.008). There were, however, no
statistical differences between the groups when the proportion of
individuals who had received ultraviolet B or psoralen + ultraviolet
A treatment were compared (p = 0.11 and p = 1.0, respectively).
No differences were observed between the two groups in relation
to stress or environmental factors other than infections.
Psoriatic arthritis had been diagnosed in 70 patients (19%) of the
study cohort, and as shown in Fig 3, it was more common in the
Cw6-negative group, although the difference was not signi®cant
(p = 0.135). Psoriatic nail changes were found in 138 (37%) of the
patients but there was no overall difference in the total incidence of
nail changes between the two groups; however, dystrophic nail
changes (Fig 3) were more common in the Cw6-negative group
(p = 0.002). There was no association between nail changes and the
age of the patients or the duration of their disease. There was a
signi®cant overall association between nail changes and psoriatic
arthritis (p = 0.01), but no difference between the Cw6-positive
and Cw6-negative groups in that respect.
No difference was observed between the groups in the
occurrence of seborrhoeic or pustular type lesions.
DISCUSSION
It is well established that psoriasis has a strong but complex genetic
background. The disease is known to skip generations and also to
appear spontaneously in individuals without affected close relatives
(Fry, 1988). The disease is strongly associated with HLA-Cw6, and
Caucasians who carry this allele have about a 10-fold increased risk
of developing psoriasis. Here we report an extensive clinical
comparison of 247 Cw6-positive and 122 Cw6-negative psoriasis
patients with a strong family history of psoriasis and certain striking
differences were observed.
Our ®ndings con®rm two reports that Cw6-positive patients
have an earlier disease onset (Ikaheimo et al, 1996; Enerback et al,
1997). The Cw6-positive patients, however, also had some
distinctly different clinical features when compared with the
Cw6-negative patients. This is particularly striking for those
features that have been most closely associated with infections by
b-hemolytic streptococci, namely acute guttate attacks (Telfer et al,
1992) and disseminated small papular eruptive lesions in patients
who also have chronic plaques (Valdimarsson et al, unpublished). It
has recently been reported that 29 patients with guttate psoriasis
were all Cw6 positive (Mallon et al, 2000). It is interesting in this
context that a higher proportion of the Cw6-positive patients in
our cohort had noted exacerbation of their disease in conjunction
with episodes of sore throat. Furthermore, the Cw6-positive
patients reported more frequently a bene®cial effect of sun-bathing
than the Cw6-negative patients. This observation and the higher
incidence of the Koebner's phenomenon may re¯ect a more
Figure 3. Sites of disease involvement at examination. The Cw6-
positive patients had more plaques at all body sites. A distinct clinical
pattern of widely distributed small papules (eruptive psoriasis), coexisting
with typical chronic plaques, was mainly observed in the Cw6-positive
patients. Nail dystrophy and arthritis were the only clinical features that
were more common in the Cw6-negative patients. The numbers above
the columns indicate p-values (ns = not signi®cant).
Figure 2. Sites and mode of disease onset in the Cw6-positive
and Cw6-negative patients. Guttate onset was mostly con®ned to the
Cw6-positive patients (p = 2 3 10±4). There was some trend for more
frequent disease presentation in the scalp (p = 0.15) or joints (p = 0.10)
in the Cw6-negative group.
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dynamic disease process in patients carrying the Cw6 allele. It has
been reported before that the Koebner's phenomenon is more
common in patients with an early disease onset (Melski et al, 1983),
but this was not observed in our study neither in the Cw6-positive
nor negative patients. Responses to ultraviolet B or psoralen + ul-
traviolet A treatments were not recorded in our study, and should
be analyzed prospectively in the context of the patients HLA-C
genotypes.
Psoriatic arthritis is known to show a familial aggregation (Moll
and Wright, 1973; Gottlieb et al, 1979) and this was also observed
in our study with an overall incidence of psoriatic arthritis of 19%.
Incidence of psoriatic arthritis in patients with psoriasis has ranged
from 5 to 15% in several reports (Salvarani et al, 1995), but has been
reported to be as high as 40% in selected patient groups (Scarpa et
al, 1984). The incidence of psoriatic arthritis in our patients may
have been biased by the selection of patients with a strong family
history. Although arthritis was more common in the Cw6-negative
group the difference was not signi®cant. Nail changes are relatively
common in psoriasis and are associated with psoriatic arthritis
(Lavaroni et al, 1994). Our ®ndings con®rm this association but it
should be noted that only dystrophic nail changes were signi®cantly
more common in the Cw6-negative patients.
We decided not to use the conventional Psoriasis and Severity
Index Score for assessing disease severity in our patients. This
scoring system is mainly useful for monitoring changes in disease
severity in individual patients during treatments. It is not suitable
for comparing disease severity in a cross-sectional evaluation of a
cohort of patients on different treatments; however, certain past and
current treatments that patients have received should help to
evaluate their overall disease severity.
This is to our knowledge one of the most extensive published
study involving comparison of clinical features in HLA-Cw6-
positive and HLA-Cw6-negative patients with psoriasis. This
applies both to the numbers of HLA typed patients and controls as
well as the clinical parameters that were analyzed. We have
con®rmed that Cw6-positive patients have an earlier disease onset
(Ikaheimo et al, 1996; Enerback et al, 1997) and that most patients
with guttate psoriasis are Cw6 positive (Mallon et al, 2000);
however, we are not aware of any previous studies reporting a
strong association between the eruptive type of psoriasis vulgaris
and Cw6 nor that Cw6-positive patients have more widely
distributed plaques, higher frequency of the Koebner's phenom-
enon, more favorable response to sunbathing, and experience
exacerbations after throat infections more frequently than Cw6-
negative patients. Furthermore, a higher frequency of dystrophic
nail changes in Cw6-negative patients has to our knowledge not
been reported before. As our ®ndings are derived from patients
with a strong family history, however, it is possible that Cw6-
positive and Cw6-negative patients without a known family history
(sporadic patients) may not show the same clinical differences as our
present cohort. Our ®ndings therefore need to be con®rmed by an
epidemiologic study before they can be generally applied to patients
with psoriasis.
It can be concluded, however, that heterogeneous genetic
predisposition of patients with psoriasis vulgaris may be associated
with different clinical features and triggering mechanisms, and
possibly also variable responses to different treatment regimens and
preventive measures.
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